Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lipocine's Enterprise Value for the quarter that ended in Mar. 2026 was €8.09 Mil.
Lipocine's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine EV-to-EBIT Related Terms
Lipocine EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Lipocine's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2VT0 vs NXTC, VYNE, QNCX: EV-to-EBIT Comparison
For the Biotechnology subindustry, Lipocine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lipocine's EV-to-EBIT falls into.
Lipocine's current Enterprise Value is €-6.19 Mil.
Lipocine's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine (STU:2VT0) has a EV-to-EBIT of 0.59 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lipocine and its competitors. According to the industry distribution chart, Lipocine ranks #70 out of 378 companies in the Biotechnology industry, placing it in the top 18.5%.
Is Lipocine's EV-to-EBIT too high?
Lipocine's current EV-to-EBIT is 0.59. The Biotechnology industry median EV-to-EBIT is 12.77. Lipocine's value of 0.59 is 95.4% below this industry median. Based on the distribution chart, Lipocine ranks #70 out of 378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lipocine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's EV-to-EBIT compare to NXTC and VYNE?
According to the Biotechnology industry distribution chart, Lipocine ranks #70 out of 378 companies for EV-to-EBIT. This places Lipocine in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 12.77. Lipocine's value of 0.59 is 95.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.77, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipocine's current EV-to-EBIT of 0.59 is 95.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lipocine and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipocine's current EV-to-EBIT is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current EV-to-EBIT of 0.59. The stock's GF Value™ is €3.51, compared to a current price of €3.94 — trading 12.4% above its estimated fair value. The current EV-to-EBIT is 0.59 and 95.4% below the Biotechnology industry median of 12.77. Lipocine's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current EV-to-EBIT is 0.59 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (STU:2VT0) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of €3.94 is trading 12.4% above its estimated GF Value™ of €3.51.
Key valuation signals for STU:2VT0:
EV-to-EBIT: 0.59
GF Value™: €3.51 vs. price of €3.94 (12.4% above fair value)
Industry Position: 95.4% below the Biotechnology median (#70 of 378)
No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
52GF Score
Get the complete analysis for STU:2VT0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2VT0 has been successfully added to your 
